Announcement on Change of Senior Executive
Filed with SSE · · 3 pages · Chinese
Earlier from BeOne Medicines
- Announcement on Key Financial Data of 1st Quarter of 2024
- Notice on Convening 2024 Annual General Meeting
- 2023 Annual Report
- Announcement on Voluntary Disclosure of European Commission's Approval of Baize'an (Tislelizumab Injection) for First-line and Second-line Treatment of Three Non-small Cell Lung Cancer Indications
- Announcement on Convening 2023 Annual Performance Meeting
Later from BeOne Medicines
- Announcement on Key Financial Data for the First Half Year of 2024
- Announcement on Convening Semi-annual Performance Briefing 2024
- Semi-annual Report in 2024
- Announcement on the Equity Registration Date for the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2024
- Announcement on the Appointment of Independent Non-executive Directors and Members of Audit Committee of the Board of Directors
Follow BeOne Medicines into a list and get an email when it puts out news.
Follow BeOne Medicines